Pharmacological profiling of recombinant tissue factor pathway inhibitor

Seminars in Thrombosis and Hemostasis

Volumn 22, Issue 2, 1996, Pages 213-219

  Jeske, Walter ^a,b   Hoppensteadt, Debra ^a   Callas, Demetra ^a   Koza, Michael J ^a   Fareed, Jawed ^a  

^a Depts Pharmacol Pathol C   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Platelets; Thrombosis; Tissue factor; Tissue factor pathway inhibitor (TFPI)

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; HEPARIN; SERINE PROTEINASE INHIBITOR;

ANIMAL MODEL; CONFERENCE PAPER; DRUG POTENCY; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBOCYTE ACTIVATION; THROMBOGENESIS; THROMBOSIS;

EID: 0029894471     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-999011     Document Type: Conference Paper

References (27)

1. Wun TC, KK Kretzmer, T Girard, JP Miletich, GJ Broze: Cloning and characterization of cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 263:6001-6004, 1988.
2. Nordfang O, SE Bjorn, S Valentin, L Nielsen, P Wildgoose, T Beck, U Hedner: The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochemistry 30:10371-10376, 1991.
3. Wesselschmidt R, K Likert, T Girard, TC Wun, G Broze: Tissue factor pathway inhibitor: The carboxy-terminus is required for optimal inhibition of factor Xa. Blood 79:2004-2010, 1992.
4. Girard T, LA Warren, WF Novotny, KM Likert, SG Brown, JP Miletich, GJ Broze: Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 338:518-520, 1989.
5. Day KC, DJ Welsch: Bacterial expression, purification, and partial characterization of amino acids 94-105 of human tissue factor pathway inhibitor (TFPI) as an inhibitor of blood coagulation. Thromb Res 68:368-381, 1992.
6. Hamamoto T, M Yamamoto, O Nordfang, J Petersen, D Foster, W Kisiel: Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). J Biol Chem 268: 8704-8710, 1993.
7. Petersen L, S Bjorn, O Nordfang: Effect of leukocyte proteinases on tissue factor pathway inhibitor. Thromb Haemostas 67:537-541, 1992.
8. Rapaport S: Regulation of the tissue factor pathway. Ann NY Acad Sci 614:51-62, 1991.
9. Goodwin CA, E Melissani, VV Kakkar, MF Scully: Plasma levels of tissue factor pathway inhibitor in thrombophilic patients. Thromb Res 72:363-366, 1993.
10. Lindahl A, P Sandset, U Abildgaard: The present status of tissue factor pathway inhibitor. Blood Coag Fibrinolysis 3:439-449, 1992.
11. Novotny WF, TJ Girard, JP Miletich, GJ Broze: Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 264:18832-18837, 1989.
12. Tollefsen D: Heparin: Basic and clinical pharmacology, In: Hoffman R, E Benz, S Shattil, B Furie, H Cohen (Eds): Hematology: Basic Principles and Practice. Churchill Livingstone, New York, 1991, pp 257-274.
13. Novotny WF, TJ Girard, JP Miletich, GJ Broze: Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein-associated coagulation inhibitor. Blood 72:2020-2025, 1988.
14. Callander N, V Rao, O Nordfang, P Sandset, B Warn-Cramer, S Rapaport: Mechanisms of binding of recombinant extrinsic pathway inhibitor (rEPI) to cultured cell surfaces. J Biol Chem 267:876-882, 1992.
15. Holst J, B Lindblad, E Wedeberg, D Bergqvist, O Nordfang, P Ostergaard, U Hedner: Tissue factor pathway inhibitor (TFPI) and its response to heparin in patients with spontaneous DVT. Thromb Res 72:467-470, 1993.
16. Kario K, T Matsuo, T Yamada, M Matsuo: Increased TFPI levels in uremic patients on regular hemodialysis. Thromb Haemostas 71:275-279, 1994.
17. Harenberg J, M Siegle, C Dempfle, G Stehle, D Heene: Protamine neutralization of the release of tissue factor pathway inhibitor activity of heparins. Thromb Haemostas 70:942-945, 1993.
18. Warn-Cramer B, S Maki, S Rapaport: Heparin-releasable and platelet pools of TFPI in rabbits. Thromb Haemostas 69:221-226, 1993.
19. Jeske W, A Kammereit, R Klauser, W Raake, P Eckenberger, D Hoppensteadt, J Fareed: Evidence for the role of tissue factor pathway inhibitor (TFPI) release in the mediation of the antithrombotic actions of low molecular weight heparins (LMWHs) and a synthetic sulfated lactobionic acid derivative, (Abst.) Blood 82(Suppl 1):273, 1993.
20. Fareed J, JM Walenga, A Kumar, A Rock: A modified stasis thrombosis model to study the antithrombotic actions of heparin and its fractions. Semin Thromb Hemostas 11:155-175, 1985.
21. Cade JF, MR Buchanan, B Boneu, PA Ockelford: A comparison of the antithrombotic and hemorrhagic effects of low molecular weight heparin fractions and the influence of preparation. Thromb Res 35:613-625, 1984.
22. Basic-Micic M, C Roman, U Herbei, E Kling, B Scholz, HK Breddin: Platelet-induced thrombin generation time: A new sensitive global assay for platelet function and coagulation. Methods and results. Haemostasis 22:309-321, 1992.
23. Wun TC: Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: Synergistic anticoagulant action between LACI and sulfated polysaccharides. Blood 79:430-438, 1992.
24. Nordfang O, S Valentin, T Beck, U Hedner: Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilic plasma. Thromb Haemostas 66:464-467, 1991.
25. Warn-Cramer B, S Rapaport: Studies of factor Xa/phospholipid-induced intravascular coagulation in rabbits. Arterioscler Thromb 13:1551-1557, 1993.
26. Khouri R, B Koudsi, F Kaiding, R Ornberg, TC Wun: Prevention of thrombosis by topical application of tissue factor pathway inhibitor in a rabbit model of vascular trauma. Ann Plastic Surg 30:398-404, 1993.
27. Creasey AA, ACK Chang, L Feigen, TC Wun, FB Taylor, LB Hinshaw: Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 91:2850-2860, 1993.